Critical Interactions Training Course (Feb 9th - Feb 10th, 2026)" training has been added to ResearchAndMarkets.com's offering. The programme will cover the regulatory strategy to adopt and the ...

This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...

Exagen Inc. (NASDAQ:XGN) Q3 2025 Earnings Call Transcript November 4, 2025 Exagen Inc. misses on earnings expectations. Reported EPS is $-0.19 EPS, expectations were $-0.13. Operator: " Ryan Douglas: ...

Delivered record total revenue of $17.2 million, representing a 38% increase compared to the third quarter of 2024, or a 26% increase before the impact of one-time adjustments recorded in 2024. Grew ...

Grew AVISE CTD test volume 16% compared to the third quarter of 2024. Expanded AVISE CTD trailing twelve-month ASP to $441 per test, an increase of $37 per test over the third quarter of 2024. Ended ...

Revenue: $17.2 million in Q3, highest quarter in history, nearly 40% increase over Q3 2024. Year-to-Date Revenue: Approximately $50 million, 19% growth through Q3. Gross Margin: Just over 58% in Q3, ...

- Revenue (GAAP) rose to $17.2 million, surpassing analyst expectations by 5.5% and grew 14.2% year over year. - AVISE CTD test volume increased 14% sequentially, and the trailing-twelve-month average ...

NEW YORK – Investment bank Craig-Hallum said Wednesday that it has initiated coverage of autoimmune testing firm Exagen with a Buy rating and a $12 price target. Analyst Bill Bonello said in a note to ...

Delivered record total revenue of $15.5 million on the strength of continued ASP expansion and AVISE CTD test volume growth. Expanded AVISE CTD trailing twelve-month ASP to $419, an increase of $42 ...